• Jason J Sico, Natasha M Antonovich, Jennifer Ballard-Hernandez, Andrew C Buelt, Amy S Grinberg, Franz J Macedo, Ian W Pace, James Reston, James Sall, Friedhelm Sandbrink, Karen M Skop, Thomas R Stark, Rebecca Vogsland, Lisa Wayman, and Aven W Ford.
• Headache Centers of Excellence Program, VA Connecticut Healthcare System, West Haven, and Yale School of Medicine, New Haven, Connecticut (J.J.S., A.S.G.).
• Ann. Intern. Med. 2024 Dec 1; 177 (12): 167516941675-1694.

DescriptionHeadache medicine and therapeutics evidence have been rapidly expanding and evolving since the 2020 U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) clinical practice guideline (CPG) for the management of headache. Therefore, the CPG was revised in 2023, earlier than the standard 5-year cycle. This article reviews the 2023 CPG recommendations relevant to primary care clinicians for treatment and prevention of migraine and tension-type headache (TTH).MethodsSubject experts from the VA and the DoD developed 12 key questions, which guided a systematic search using predefined inclusion and exclusion criteria. After reviewing evidence from 5 databases published between 6 March 2019 and 16 August 2022, the work group considered the strength and quality of the evidence, patient preferences, and benefits versus harms on critical outcomes before making consensus recommendations.RecommendationsThe revised CPG includes 52 recommendations on evaluation, pharmacotherapy, invasive interventions, and nonpharmacologic interventions for selected primary and secondary headache disorders. In addition to triptans and aspirin-acetaminophen-caffeine, newer calcitonin gene-related peptide (CGRP) inhibitors (gepants) are options for treatment of acute migraine. Medications to prevent episodic migraine (EM) include angiotensin-receptor blockers, lisinopril, magnesium, topiramate, valproate, memantine, the newer CGRP monoclonal antibodies, and atogepant. AbobotulinumtoxinA can be used for prevention of chronic migraine but not EM. Gabapentin is not recommended for prevention of EM. Ibuprofen (400 mg) and acetaminophen (1000 mg) can be used for treatment of TTH, and amitriptyline for prevention of chronic TTH. Physical therapy or aerobic exercise can be used in management of TTH and migraines.

37 keywords...

hide…